Side-by-side comparison of AI visibility scores, market position, and capabilities
German athletic brand with €8.6B revenue bridging performance and lifestyle; soccer, motorsport, and Ferrari partnerships with streetwear collaborations competing with Nike and Adidas.
PUMA is a German multinational athletic footwear, apparel, and accessories company known for its sport-lifestyle positioning — bridging performance sports (soccer, running, motorsport) with streetwear and fashion culture through collaborations with athletes, designers, and cultural icons. Listed on the Frankfurt Stock Exchange (XETRA: PUM) and headquartered in Herzogenaurach, Germany (the same city as rival Adidas), PUMA generates approximately €8.6 billion ($9 billion) in annual revenue and is controlled by Kering (the French luxury group owning Gucci, Saint Laurent, and Balenciaga).\n\nPUMA's product strategy spans performance sports (soccer cleats, running shoes, motorsport racing gear) and lifestyle/fashion (Suede sneakers, RS-X chunky shoes, Clyde Basketball). PUMA's ambassador roster reflects this dual identity — Neymar Jr. and world-class soccer players for performance credibility, alongside cultural figures and streetwear collaborations for lifestyle relevance. The Motorsport heritage (Ferrari team apparel, licensing partnerships with Formula 1 teams) provides a distinctive motorsport-luxury positioning that neither Nike nor Adidas can match.\n\nIn 2025, PUMA competes with Nike, Adidas, and New Balance for global athletic footwear and apparel market share. The brand sits in the #3 position globally in athletic footwear by volume but has strong regional positions — PUMA is particularly competitive in soccer (a global No. 3 player with significant national team and club sponsorships), motorsport apparel, and running. The 2025 strategy focuses on the "Forever Faster" repositioning that emphasizes performance credentials, growing the Direct-to-Consumer business for margin improvement, and expanding in the fast-growing Asia Pacific market where PUMA has room to grow relative to its European strength.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.